The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Open accessAbstract
BACKGROUND: Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele. This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir. METHODS: This double-blind, prospective, randomized study involved 1956 patients from 19 countries, who were infected with human immunodeficiency virus type 1 and who had not previously received abacavir. We randomly assigned patients to undergo prospective HLA-B*5701 screening, with exclusion of HLA-B*5701-positive patients from abacavir treatment (prospective-screening group), or to undergo a standard-of-care approach of abacavir use without prospective HLA-B*5701 screening (control group). All patients who started abacavir were observed for 6 weeks. To immunologically confirm, and enhance the specificity of, the clinical diagnosis of hypersensitivity reaction to abacavir, we performed epicutaneous patch testing with the use of abacavir. RESULTS: The prevalence of HLA-B*5701 was 5.6% (109 of 1956 patients). Of the patients receiving abacavir, 72% were men, 84% were white, and 18% had not previously received antiretroviral therapy. Screening eliminated immunologically confirmed hypersensitivity reaction (0% in the prospective-screening group vs. 2.7% in the control group, P<0.001), with a negative predictive value of 100% and a positive predictive value of 47.9%. Hypersensitivity reaction was clinically diagnosed in 93 patients, with a significantly lower incidence in the prospective-screening group (3.4%) than in the control group (7.8%) (P<0.001). CONCLUSIONS: HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir. Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Self-citationGenetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Self-citationMartin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307067101 · Cited by 452
Self-citationSaag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., Stancil, B., Mosteller, M., Brothers, C., Wannamaker, P., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529382 · Cited by 425
Self-citationHetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C., & Mallal, S. (2006) · Clinical Infectious Diseases · doi:10.1086/504874 · Cited by 296
Self-citationDeJesus, E., Herrera, G., Teofilo, E., Gerstoft, J., Buendia, C. B., Brand, J. D., Brothers, C. H., Hernandez, J., Castillo, S. A., Bonny, T., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424009 · Cited by 226
Gulick, R. M. (2006) · JAMA · doi:10.1001/jama.296.7.769 · Cited by 219
Clinical and immunogenetic correlates of abacavir hypersensitivity
Phillips, E. J., Wong, G. A., Kaul, R., Shahabi, K., Nolan, D. A., Knowles, S. R., Martin, A. M., Mallal, S. A., & Shear, N. H. (2005) · AIDS · doi:10.1097/01.aids.0000171414.99409.fb · Cited by 198
Self-citationUtility of patch testing in patients with hypersensitivity syndromes associated with abacavir
Phillips, E. J., Sullivan, J. R., Knowles, S. R., & Shear, N. H. (2002) · AIDS · doi:10.1097/00002030-200211080-00017 · Cited by 145
Self-citationHughes, S. H., Hughes, A. R., Brothers, C. H., Spreen, W. R., & Thorborn, D. E. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.286 · Cited by 53
Self-citation
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Venkatesan, A., Tunkel, A. R., Bloch, K. C., Lauring, A. S., Sejvar, J., Bitnun, A., Stahl, J.-P., Mailles, A., Drebot, M., Rupprecht, C. E., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit458 · Cited by 1,197
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Genetic analyses of diverse populations improves discovery for complex traits
Wojcik, G. L., Graff, M., Nishimura, K. K., Tao, R., Haessler, J., Gignoux, C. R., Highland, H. M., Patel, Y. M., Sorokin, E. P., Avery, C. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1310-4 · Cited by 1,033
Hammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Metadata
- Authors
- Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D., & Benbow, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-02-07
- Volume
- 358
- Issue
- 6
- Pages
- 568-579
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112182958
- Cited by
- 1,835
- References
- 12
- FWCI
- 97.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.